NeuroSense Therapeutics L... (NRSN)
0.97
-0.04 (-3.96%)
At close: Apr 23, 2025, 3:59 PM
1.00
3.54%
Pre-market: Apr 24, 2025, 07:07 AM EDT
Company Description
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases.
Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis.
The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease.
NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
NeuroSense Therapeutics Ltd.

Country | IL |
IPO Date | Dec 9, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 17 |
CEO | Alon Ben-Noon |
Contact Details
Address: Building B Herzliya, IL | |
Website | https://www.neurosense-tx.com |
Stock Details
Ticker Symbol | NRSN |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001875091 |
CUSIP Number | M74240108 |
ISIN Number | IL0011809592 |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Alon Ben-Noon | Co-Founder, Chief Executive Officer & Director |
Dr. Niva Russek-Blum Ph.D. | Chief Technology Officer |
Or Eisenberg | Chief Financial Officer |
Dr. Ferenc Tracik M.D. | Chief Medical Officer |
Eidan Loushi | C.R.A. |
Hagit Binder | Chief Operation Officer |
Keren Pushett | Head of HR |
Yael Barak | Vice President of Quality & Compliance |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 11, 2025 | POS AM | Filing |
Apr 11, 2025 | POS AM | Filing |
Apr 07, 2025 | 6-K | Filing |
Apr 07, 2025 | 20-F | Filing |
Mar 27, 2025 | 6-K | Filing |
Mar 19, 2025 | 6-K | Filing |
Feb 21, 2025 | 424B5 | Filing |
Feb 19, 2025 | 6-K | Filing |
Jan 17, 2025 | 424B3 | Filing |
Jan 06, 2025 | 6-K | Filing |